New drug cuts down genetically inherited heart disease risk factor
Lepodisiran, an experimental drug from the pharmaceutical company Eli Lilly, is a small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease, according to a press release Sunday.
'Nearly a quarter of the world's population has elevated levels of Lp(a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,' said Steven Nissen, chief academic officer of the Heart, Vascular & Thoracic Institute at the Cleveland Clinic.
'Unfortunately, there are no approved cholesterol-lowering therapies specifically for this genetic risk factor, and lifestyle changes like diet and exercise do not provide meaningful reductions,' Nissan added.
But, he continued, 'these significant and sustained Lp(a) reductions are encouraging and suggest that siRNA approaches like lepodisiran could potentially offer durable benefits with long-term dosing.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
UK patients rush for obesity jab before Eli Lilly raises price 170% to appease Donald Trump
Patients are racing to secure the weight loss drug Mounjaro ahead of a price rise of up to 170 per cent in the UK, as drugmaker Eli Lilly
Yahoo
3 hours ago
- Yahoo
UK pharmacist says Eli Lilly's Mounjaro price hike a 'shock'
Eli Lilly will increase the UK list price of its blockbuster drug Mounjaro (tirzepatide) amid pressure from US President Donald Trump for drugmakers to hike prices outside the US. In the UK, Mounjaro is indicated for the treatment of type 2 diabetes (T2D) and weight loss. In the US, the name Mounjaro is only used for T2D while Eli Lilly markets tirzepatide for weight loss in the US under the brand name Zepbound. Mounjaro generated global sales of $5.2bn in Q2 alone, up 68% from the same period last year. In a statement sent to Pharmaceutical Technology, Eli Lilly said that the price changes will not affect the drug's availability on the UK's National Health Service (NHS), saying it had 'reached an agreement with the healthcare system to ensure continued supply and patient access'. The drugmaker added: 'While Lilly does not determine the prices that private healthcare providers set, we are working with them to maintain patient access.' Mounjaro's current list price in the UK ranges from £92 (approximately $125) to £122 a month, depending on the dose, according to Eli Lilly. The drug's new list price will increase to between £133 and £330 starting on 1 September. GlobalData said in a research note: "For the UK, this latest step by Eli Lilly may potentially be seen as the start of a wave of higher medicine prices than the country has been accustomed to in recent years. Heading into 2026, [we] may expect to see a narrowing of the gap between the US and UK (and potentially between the US and EU) pricing for some new medicines." When it was rolled out in the UK in February 2024, Eli Lilly agreed to a list price 'significantly below' that of other competitor European markets to stop delays in the availability of the medicine to diabetes patients through the NHS. A pharmacist in London, who wishes to remain anonymous, told Pharmaceutical Technology: 'I was shocked today with the email that we pharmacists received about Mounjaro's price increase. We have so many patients on this medicine, and now half of them will be really struggling to pay for it. 'I already have some of them asking me for discounts and with the increase, that will be impossible. I feel really sad for patients who use the injection to control their blood sugar levels and now they might not be able to do so. Why did the manufacturer wait so long to make this price change?' Dr Leyla Hannbeck, CEO of the Independent Pharmacies Association (IPA), said: "We are shocked and very disappointed," while reacting to the news. Lilly said the changes, which follow a pricing review, 'address pricing inconsistencies compared to other developed countries, including in Europe'. International pricing pressures also contributed to the mark-up, according to the company. President Trump has been pressuring US drugmakers to cut prices of prescription medicines in the country, which cost around three times more than identical counterparts in other developed nations. He famously relayed a phone call he took from a friend in the UK, who complained about a 'damn fat drug' that cost $88 in London but $1,300 in New York. The stark difference in costs for weight loss drugs was one of the factors that led Trump to introduce the Most Favoured Nation (MFN) policy, a framework that would tie US drug prices to the lowest prices in other developed countries. Amid pushback from the industry, Trump sent letters to leading pharma companies, including Eli Lilly, calling on them to take more steps to lower prices. '[Eli] Lilly agrees with the policy objective expressed in the executive order that research costs for breakthrough medicines should be shared more fairly across developed countries. However, a Most Favoured Nation approach is not the answer to help patient affordability,' Eli Lilly told Pharmaceutical Technology. "IPA calls on the other weight-loss manufacturers to hold their nerves and hold their prices. The British market for weight-loss jabs will is only set to grow, but it will only achieve that growth if treatment remains affordable to the average patient," Dr Hannbeck commented. "UK pharmacist says Eli Lilly's Mounjaro price hike a 'shock'" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
CNN
3 hours ago
- CNN
Eli Lilly hikes Mounjaro prices in the UK to make weight-loss drug cheaper in the US
Eli Lilly will significantly increase the price of its weight-loss drug Mounjaro in the United Kingdom in a bid to bring down prices in the United States after weeks of pressure from the Trump administration. The US drugmaker announced Thursday that it was rolling out price hikes across Europe, with prices rising in the UK from September. The price of a month's supply of the highest dose of Mounjaro in the UK will rise from £122 ($165) to £330 ($447), Eli Lilly confirmed to CNN, representing a 170% increase. Eli Lilly (LLY) confirmed that prices for Mounjaro accessed through the NHS, the UK's public health service, would remain unchanged. Around 220,000 Brits are expected to access Mounjaro, which is also used by diabetics, through the NHS in the first three years of its introduction. Private suppliers will be able to negotiate with Eli Lilly in an attempt to gain discounts. Following Eli Lilly's announcement, Juniper, a private weight-loss clinic in the UK, published a blog offering Mounjaro patients a pathway to switch to Wegovy, a competing weight-loss jab manufactured by Danish group Novo Nordisk (NVO). In a statement to CNN, a spokesperson for Eli Lilly said the company had originally agreed a UK list price that was significantly below the European average to prevent delays in NHS availability when Mounjaro was first launched in the country. 'With changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation,' the spokesperson said. US pharmaceutical companies have faced intense pressure from President Donald Trump over the disparity in drug prices between the United States and Europe. Trump has accused foreign nations of 'freeloading' at the expense of American innovation. Eli Lilly said in its statement that it was committed to keeping the United States as the global leader in drug research and manufacturing. The drugmaker said it had in recent months 'intensified efforts to align prices across developed countries, especially in Europe.' 'This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US,' the company said in the statement. In July, Trump sent letters to 17 major pharmaceutical companies, including Eli Lilly, ordering them to lower the price of prescription drugs in the United States. At the time, Chris Meekins, managing director of health policy research at Raymond James, told CNN that, while pressure from Trump may result in price increases or delayed access to drugs in other countries, it was unlikely to directly help the American consumer. Trump signed an executive order in May that aimed to force US pharmaceutical companies to bring European and US drug prices into harmony under a 'Most Favored Nation' rule. While several experts have previously told CNN that Trump has limited legal power to force drugmakers to lower domestic prices, his efforts indicate a strong political will that could lead to drugmakers changing their pricing voluntarily. The president has been particularly critical of the price disparity in weight-loss drugs across the Atlantic Ocean. Speaking in May upon signing his executive order, Trump referenced a conversation with a friend who complained about the difference in the pricing of what Trump called the 'fat shot drug' between the UK and the US. 'He said, 'I just paid $88, and in New York I paid $1,300. What the hell is going on?' So, I checked, and it's the same box made in the same plant by the same company,' Trump said.
